Kawamura Y, Uchijima Y, Horike N, Tonami K, Nishiyama K, Amano T, et al
In studies with rats or mice, dulaglutide and medicines that work like dulaglutide caused thyroid tumors, including thyroid cancer
It directly makes the user uncomfortable
In addition to this, Semaglutide exemplified a secure and well-tolerated portrayal beyond the program, with the most frequent unfavorable incidents being gastrointestinal
Clinical data suggest that many patients lose approximately 1-2% of their baseline weight in the first four weeks, though individual results vary considerably, with some experiencing minimal change during this initial period
Sporadic case reports and stories on the internet about the effects of other GLP-1-based drugs are emerging